David Paul, Managing Director of VectorVest in the UK joined us to talk through stock picking fundamentals, technical analysis and more. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

AstraZeneca given EU approval for use of Koselugo in children

Tue, 22nd Jun 2021 08:25

(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Koselugo drug had been approved for use in children with neurofibromatosis type 1 and plexiform neurofibromas across the European Union.
AstraZeneca highlighted that the approval of Koselugo in patients with NF1, a debilitating genetic condition where tumours develop on the nerve sheaths, made it the first medicine to have been approved to treat the condition in the EU.

The FTSE 100-listed firm stated that the approval by the European Commission was based on positive results from a Sprint Stratum 1 Phase II trial sponsored by the National Institute of Health's National Cancer Institute cancer therapy evaluation program, which showed that Koselugo reduced the size of inoperable tumours in children, reducing pain and improving quality of life.

Dave Fredrickson, vice President of AZN's oncology business, said: "As the first medicine approved in the EU for patients with neurofibromatosis type 1, Koselugo has the potential to transform the way plexiform neurofibromas are managed and treated.

"The Sprint data showed that Koselugo not only shrank tumours in some children, but also reduced pain and improved their quality of life. This significant milestone was made possible thanks to our research partners, the National Cancer Institute, the Neurofibromatosis Therapeutic Acceleration Program, the Children's Tumor Foundation, the patient community and every child, parent and doctor involved in the clinical trial."

As of 0820 BST, AstraZeneca shares were down 0.74% at 8,345.72p.

Related Shares

More News

TOP NEWS: AstraZeneca vaccine effective after one dose, study shows

TOP NEWS: AstraZeneca vaccine effective after one dose, study shows

23 Jul 21 10:30

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

22 Jul 21 16:03

EXECUTIVE CHANGES: Nuformix responds to "frustration" as CEO departs

EXECUTIVE CHANGES: Nuformix responds to "frustration" as CEO departs

22 Jul 21 14:29

AstraZeneca completes buy of rare diseases specialist Alexion

AstraZeneca completes buy of rare diseases specialist Alexion

21 Jul 21 16:48

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.